Readily3D SA, the leading company in tomographie volumetric bioprinting, today announced a renewed leadership team as itenters its next phase of growth.
Dr. Diego Dupouy has been appointed Chief Executive Officer. He co-founded Lunaphore Technologies, the Swiss spatial biology company acquired by Bio-Techne in 2023, where as Chief Technology Officer he took the company’s instrument from a prototype to a product shipping to pharma and academic laboratories worldwide.
Dr. Nathalie Brandenberg joins as Chief Scientific Officer. She co-founded SUN bioscience and DOPPL, with its flagship technology, Gri3D and associated organoid services. DOPPL was acquired by lnSphero AG in 2025.
Dr. Paul Delrot, who co-founded Readily3D in 2020 and has led it as CEO since November 2022, becomes Chief Technology Officer.
Under Delrot, Readily3D took volumetric bioprinting from a prototype to a commercial product, Tomolite, now installed in laboratories in more than 15 countries across Europe, North America and Asia-Pacific.
Customers have published more than 50 peer-reviewed papers using Tomolite.
Where the company is headed
With this unique combination of expertise, the company’s objective is to scale a proven product into a new standard.
The company’s priorities are set to grow manufacturing and commercial capacity, strengthen its presence in territories beyond Europe – particularly North America and Asia-Pacific – and open new applications for the technology beyond its strongly established base.
